Novo Nordisk: Cheap Entry Into a Dominant, Resilient Franchise
Novo Nordisk is trading at a valuation that looks unusually cheap for a global leader in diabetes and obesity care. Recent legal wins, a raised full-year outlook and a still-healthy cash-generating core argue for a tactical long. This trade idea gives an entry, stop and target with horizon and risk framing.